guidos por los trastornos de ansiedad y los trastornos depresivos.

Del total de menores que recibieron atención, más de la mitad fue incluida al programa de intervención psicoeducativa, menos de una cuarta parte requirió seguimiento en consulta externa y solamente un caso requirió seguimiento en consulta externa. Consideramos prioridad, para todas las instituciones de nuestro país, que se elaboren guías o manuales clínicos de intervención en crisis para futuros casos de desastre.

Emmanuel Isais Samiento-Hernández, Psq;
Rosa Elena Ulloa-Flores, Psq; Neurofarm;
Jorge Ramírez-Ahua, Psq;
Víctor Manuel Velázquez-López, Psq;
Juan Carlos Reséndez-Aparicio, Neurol;
Maricruz Rodríguez-Arévalo, Psic.

Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Ciudad de México, México.

https://doi.org/10.21149/9928

Declaración de conflicto de intereses. Los autores declararon no tener conflicto de intereses.

Referencias


Response to “New tobacco products, a threat for tobacco control and public health of Mexico”

Dear Editor: The position article by Reynales-Shigematsu and colleagues on the public health impact in Mexico of combustion-free electronic nicotine delivery systems (ENDS) fails to present a balanced overview of the risk-benefit ratio of these new technologies, grossly misrepresents the existing evidence, and ignores the broad consensus that these products are much less harmful than cigarettes.

The work cited by the authors (references 8-21) on exposure risks from e-cigarette aerosol emissions report misleading results that do not reflect normal conditions of use. The authors claim that trial of e-cigarettes is propitiating tobacco initiation among Mexican adolescents, citing a longitudinal cohort study on Mexican high school students (reference 31) which actually disproves this claim, as it reported that the association between e-cigarette trial at baseline and past 30 day smoking at follow-up was not even statistically significant. The authors dismiss the utility of e-cigarettes in smoking cessation, but their cited references do not support this claim.

Further, a recent high quality randomized controlled trial8 has shown e-cigarettes to be twice as effective in smoking cessation compared to nicotine replacement therapies. A detailed critique of the position article is available.

Following the authors, ENDS can only be part of a harm reduction strategy for Mexico if they immediately promote total smoking abstinence, as well as complete absence of dual usage and recruitment of non-smokers. However, these are maximalist and unrealistic conditions that no new harm reduction product can fulfill. A more realistic approach to harm reduction yields concrete benefits: the recreational usage of e-cigarettes, endorsed by health institutions in the United Kingdom under a consistent Tobacco Control strategy, has contributed to a significant decay of smoking prevalence with negligible usage by non-smokers of all ages.

By presenting ENDS as a threat to public health (consequently recommending their regulation as combustible tobacco products), Reynales-Shigematsu and colleagues are depriving 15 million Mexican smokers of key information on a plausible harm reduction alternative that can vastly improve their health. As an unintended consequence, this misinformation will keep them smoking.

Riccardo Polosa, MD, PhD,(1,2)
polosa@unic.it
Salvatore Urso, MSC,(1)
Konstantinos E Farsalinos, MD, MPH,(1,2,3)
Emmanuel Isaías Sarmiento-Hernández, Psiq,(1)
Rosa Elena Ulloa-Flores, Psiq; Neurofarm,(1)
Jorge Ramírez-Ahua, Psq,(1)
Víctor Manuel Velázquez-López, Psq,(1)
Juan Carlos Reséndez-Aparicio, Neurol,(1)
Maricruz Rodríguez-Arévalo, Psic.(1)
(1) Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Ciudad de México, México.
(2) Center of Excellence for the Acceleration of Harm Reduction (Coera), University of Catania. Catania, Italy.
(3) Department of Pharmacy, University of Catania. Catania, Italy.
(4) Department of Cardiology, Onasis Cardiac Surgery Centre. Kallithea, Greece
(5) National School of Public Health. Athens, Greece.

https://doi.org/10.21149/10128

Declaración de conflicto de intereses. Riccardo Polosa has received lecture fees and research funding from manufacturers of stop smoking medications (Pfizer and GlaxoSmithKline) as well as manufacturers of drugs for the management of smoking-related diseases (CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer, Ingelheim, Novartis, Duska Therapeutics and Forest Laboratories). He
has also received support from The Consumer Advocates for Smoke-free Alternatives (CASAA) for publication and open access costs of one paper. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl, and Health Diplomats (consulting company that delivers solutions to global health problems with special emphasis on harm minimization). Lectures fees from a number of European electronic cigarette industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vapers advocacy no-profit organizations. He is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League) and for The Consumer Advocates for Smoke-free Alternatives (CASAA); Chair of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). Salvatore Urso has no conflict of interest to report. Konstantinos E Farsalinos has no conflict of interest to report for the past three years. For the past five years, two of his studies were funded by the non-profit association AEMSA and one study was funded by the non-profit association Tennessee Smoke-Free Association.

References